OBJECTIVE: To measure the effects of fluoxetine and pemoline on heart period and QT variability. METHODS:Healthy volunteers were randomly assigned treatment with 20 mg daily of fluoxetine (n=7), 56.25 mg of pemoline (n=7) or placebo (n=9). Twenty-four-hour Holter ECGs were obtained before and after approximately 8 weeks of double-blind treatment. RESULTS: There were no significant changes in the fluoxetine group. Pemoline was associated with a significant decrease in the high frequency (HF) power (0.15-0.5 Hz, P=.02) and fractal dimension of RR time series (P=.03). QTvi, a measure of QT interval variability, increased in the pemoline group (P=.05). CONCLUSION:Pemoline, but not fluoxetine, decreases heart period variability (HPV) in the HF power, suggesting a vagolytic effect on cardiac autonomic function. Pemoline is also associated with an increase in QT interval variability, a measure that is sensitive to adrenergic agonists.
RCT Entities:
OBJECTIVE: To measure the effects of fluoxetine and pemoline on heart period and QT variability. METHODS: Healthy volunteers were randomly assigned treatment with 20 mg daily of fluoxetine (n=7), 56.25 mg of pemoline (n=7) or placebo (n=9). Twenty-four-hour Holter ECGs were obtained before and after approximately 8 weeks of double-blind treatment. RESULTS: There were no significant changes in the fluoxetine group. Pemoline was associated with a significant decrease in the high frequency (HF) power (0.15-0.5 Hz, P=.02) and fractal dimension of RR time series (P=.03). QTvi, a measure of QT interval variability, increased in the pemoline group (P=.05). CONCLUSION:Pemoline, but not fluoxetine, decreases heart period variability (HPV) in the HF power, suggesting a vagolytic effect on cardiac autonomic function. Pemoline is also associated with an increase in QT interval variability, a measure that is sensitive to adrenergic agonists.
Authors: Michael K Boettger; Steffen Schulz; Sandy Berger; Manuel Tancer; Vikram K Yeragani; Andreas Voss; Karl-Jürgen Bär Journal: Ann Noninvasive Electrocardiol Date: 2010-04 Impact factor: 1.468
Authors: Andrew H Kemp; Tim Outhred; Sasha Saunders; Andre R Brunoni; Pradeep J Nathan; Gin S Malhi Journal: Psychopharmacology (Berl) Date: 2013-12-15 Impact factor: 4.530
Authors: Nagaraj Desai; D S Raghunandan; Mallika Mallavarapu; Ronald D Berger; Vikram K Yeragani Journal: Ann Noninvasive Electrocardiol Date: 2004-10 Impact factor: 1.468
Authors: Ripu D Jindal; Matcheri S Keshavan; Kevin Eklund; Angela Stevens; Debra M Montrose; Vikram K Yeragani Journal: Schizophr Res Date: 2009-07-01 Impact factor: 4.939
Authors: Christine M Clark; Charles G Frye; Margaret C Wardle; Greg J Norman; Harriet de Wit Journal: Psychophysiology Date: 2014-09-11 Impact factor: 4.016